Miruvor
Sign up
The short answer

What studies of PEMF found

10papers on PEMF
11people in 3 studies testing PEMF alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the placebo trial (low certainty): 3 findings, all B.

7 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: PEMF may help for long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 10 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. PEMF · Long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue2 studies · 10 people received PEMF Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (20 in all).

The placebo trial20 randomised · 5 weeks · For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min

Fatigue improved more than in the comparison group.

PEMF may reduce fatigue in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (20 in all)

Studies with no comparison group1 study · 5 weeks · 10 sessions, twice weekly for 5 weeks (few people)

Fatigue improved.

The evidence is very uncertain about the effect of PEMF on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people, or how many isn't reported
  • Not all results were tested against chance
See the 2 studies
  1. Feasibility, acceptance and effects of pulsed magnetic field therapy in patients with post-COVID-19 fatigue syndrome : A randomized controlled pilot study. (2025)

    People in the study
    20 randomised
    Dose
    For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min
    Outcome
    MFI Mental Fatigue Multidimensional Fatigue Inventory
    Effect
    better (not tested)
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    Mood Brief Fatigue Inventory
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 10 people received PEMF Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (20 in all).

The placebo trial20 randomised · 5 weeks · For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min

Sleep improved more than in the comparison group.

PEMF may improve sleep in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (20 in all)
See the 1 study
  1. Feasibility, acceptance and effects of pulsed magnetic field therapy in patients with post-COVID-19 fatigue syndrome : A randomized controlled pilot study. (2025)

    People in the study
    20 randomised
    Dose
    For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min
    Outcome
    ISI Insomnia Severity Index
    Effect
    better (not tested)
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Anxiety1 study Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.

Studies with no comparison group1 study · 5 weeks · 10 sessions, twice weekly for 5 weeks (few people)

Anxiety improved.

The evidence is very uncertain about the effect of PEMF on anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people, or how many isn't reported
  • Not all results were tested against chance
See the 1 study
  1. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    GAD‑7 Generalized Anxiety Disorder 7
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Depression1 study Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.

Studies with no comparison group1 study · 5 weeks · 10 sessions, twice weekly for 5 weeks (few people)

Depression improved.

The evidence is very uncertain about the effect of PEMF on depression in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people, or how many isn't reported
  • Not all results were tested against chance
See the 1 study
  1. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    PHQ‑9 Patient Health Questionnaire 9
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Quality of life2 studies · 10 people received PEMF Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (20 in all).

The placebo trial20 randomised · 5 weeks · For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min

Quality of life improved more than in the comparison group.

PEMF may improve quality of life in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (20 in all)

Studies with no comparison group1 study · 5 weeks · 10 sessions, twice weekly for 5 weeks (few people)

Quality of life improved.

The evidence is very uncertain about the effect of PEMF on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people, or how many isn't reported
  • Not all results were tested against chance
See the 2 studies
  1. Feasibility, acceptance and effects of pulsed magnetic field therapy in patients with post-COVID-19 fatigue syndrome : A randomized controlled pilot study. (2025)

    People in the study
    20 randomised
    Dose
    For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min
    Outcome
    SF-36 PCS Short Form Health Survey
    Effect
    better (not tested)
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    SF-36 Physical functioning Short Form (SF-36) Health Survey
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning3 studies · 11 people received PEMF Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 20 people found no clear difference; a small benefit can't be ruled out; effect size 0.00 (very small); inconsistency: 2 studies without a placebo group found improvement.

The placebo trial20 randomised · 5 weeks · For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min

No clear difference in daily functioning.

The evidence is very uncertain about the effect of PEMF on daily functioning in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 20 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares PEMF with placebo.

Studies with no comparison group2 studies · 1 person with results (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of PEMF on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 3 studies
  1. Feasibility, acceptance and effects of pulsed magnetic field therapy in patients with post-COVID-19 fatigue syndrome : A randomized controlled pilot study. (2025)

    People in the study
    20 randomised
    Dose
    For all positions 100% of maximum power (about 96 W) was chosen, except for the pelvic floor when 75% of maximum power was used, The patients received 10 sessions of PEMF twice weekly for 5 weeks. Each session lasted 30 min
    Outcome
    PCFS Post Covid Functional Status Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    patient-reported activities no longer a problem
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  3. Case report: Individualized pulsed electromagnetic field therapy in a Long COVID patient using the Adaptive Force as biomarker. (2022)

    People in the study
    1 in the study
    Dose
    550 Hz (flux density 1 mT), Only one treatment was performed
    Outcome
    exercise capacity
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms2 studies · 1 (few people) person received PEMF Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 1 person with results (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of PEMF on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report. (2022)

    People in the study
    —
    Dose
    10 sessions, twice weekly for 5 weeks
    Outcome
    persistence of improvements at 6 weeks
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Case report: Individualized pulsed electromagnetic field therapy in a Long COVID patient using the Adaptive Force as biomarker. (2022)

    People in the study
    1 in the study
    Dose
    550 Hz (flux density 1 mT), Only one treatment was performed
    Outcome
    Subjective Long COVID symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects1 study
Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue2 studies
Headache2 studies

All papers

  1. Successful application of pulsed electromagnetic fields in a patient with post-COVID-19 fatigue: a case report.2022 · case report
    Summary

    This case report described one 55-year-old female with post-COVID-19 fatigue syndrome at an outpatient clinic. She received 10 sessions of pulsed electromagnetic field treatment with the Papimi device twice weekly for 5 weeks, each session lasting 30 min, with no comparison group and no randomisation. The authors measured patient-reported fatigue, work ability, quality of life, stress, depression, anxiety and resilience before treatment, immediately after treatment, and 6 weeks after treatment. The BFI total score was 6.33 before treatment, 0.22 immediately after, and 0.11 6 weeks after. The WAI score was 21.5 before and 40 after treatment. The PSS-10 total score was 43 before and 16 after; PHQ-9 was 16 before, 2 after and 1 at follow-up; GAD-7 was 13 before and 2 after and at follow-up; BRS was 2.67 before and 4.67 after and at follow-up. The authors reported no significant side effects apart from an increase in neck pain during local PEMF application, which disappeared after adapting treatment intensity, and a short-term increase in fatigue after the first session. They stated that factors other than PEMF may have contributed to improvement and that clinical sham-controlled studies are needed.

  2. Case report: Individualized pulsed electromagnetic field therapy in a Long COVID patient using the Adaptive Force as biomarker.2022 · case report · 1 in the study
    Summary

    This case report describes one severely affected Long COVID patient who presented to an integrative medicine practice. She received individualized pulsed electromagnetic field (PEMF) therapy via a coil to the area of C7/T1 at 550 Hz (flux density 1 mT) for ~15 min; only one treatment was performed. There was no comparison group. Adaptive Force (AF) was assessed by an objectified manual muscle test of elbow and hip flexors, and Long COVID symptom intensity was rated on a 0-no to 10-very strong scale at 1-day, 4-weeks, and ~6-month post-treatment. Before treatment, AFisomax was 71 N (~44% AFmax) for elbow flexors and 62 N (~28% AFmax) for hip flexors. Immediately post-treatment, AFisomax increased to 184 N (~100% AFmax) at the elbow and ~210 N (~100% AFmax) at the hip; isometric holding capacity increased by 2.6 (elbow) and 3.4-fold (hip). Subjective Long COVID symptoms resolved the following day. Symptom intensity improved 1-day post-treatment and sustained to 6-month post-treatment; at 4 weeks maximal holding capacity remained ~100% AFmax and the patient was symptom-free, and at 6 months symptoms had not returned. The authors report an unanticipated sympathetic hyper activation that dissolved the next day, and headache, fatigue, concentration problems and sensitivity to stimuli for 3 days after a lymph drainage independent of the intervention.

  3. [The use of grape polyphenols in combination with magnetic therapy in patients with bronchial asthma who have suffered a new coronavirus infection].2025 · combination: given with other treatments · 50 in the study
    Summary

    The study enrolled 50 patients with asthma and a history of new coronavirus infection with manifestations of postcovid syndrome, referred for sanatorium treatment to the Department of Pulmonology of the Sechenov Institute in Yalta. The intervention group (n=20) received, in addition to standard sanatorium treatment, a concentrate of polyphenols of Fenokor grapes produced by Resfood LLC and a course of low-intensity magnetic therapy using a low-frequency magnetic therapy unit. The control group consisted of 30 patients comparable in gender and age. The follow-up was after a course of sanatorium treatment; treatment duration was not reported. The paper lists measurement of C-reactive protein (CRP), zonulin, lipopolysaccharide (LPS), sCD14, LPS-binding protein and bactericidal protein that increases bacterial permeability (BPI). The abstract reports a significant decrease in CRP in the intervention group and a statistically significant increase in BPI, sCD14 and zonulin in both groups; no significant change in CRP was found in the control group. Harms, withdrawals and the number analysed were not reported. The authors state that sanatorium treatment can contribute to stress and changes in intestinal permeability and that additional research is required.

  4. Effectiveness of Non-Pharmacological Interventions for Fatigue in Long COVID: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026 · systematic review
    Summary

    This systematic review and meta-analysis included 13 RCTs with 1276 participants with long COVID. It compared non-pharmacological interventions—exercise training, cognitive behavioural therapy, non-invasive neuromodulation, and nutritional supplementation—with control conditions. Fatigue severity was assessed with validated instruments. The review reported that exercise training was the only modality associated with a statistically significant reduction in fatigue. For CBT, non-invasive neuromodulation, and nutritional supplementation, the review did not observe a statistically significant pooled effect. The difference in effects between intervention modalities was not statistically significant (p = 0.286). Harms were reported in several trials: two participants discontinued the exercise intervention (transient worsening of fatigue), and 2 participants of the training groups stopped (worsening of their symptoms in response to the intervention). In one trial there were eight AEs (four PEM, two musculoskeletal issues, one nausea and one atypical chest pain) and one unrelated SAE. In another, eight of the sixteen patients receiving active tDCS and nine of the seventeen assigned to sham tDCS experienced mild to moderate side effects such as burning or tingling. The review notes that overall certainty is low to moderate, with substantial between-study heterogeneity and limited RCTs for non-exercise interventions.

  5. Effectiveness of Rehabilitation Interventions on Adults With COVID-19 and Post-COVID-19 Condition. A Systematic Review With Meta-analysis.2024 · systematic review
    Summary

    This systematic review with meta-analysis asked whether rehabilitation interventions help adults with COVID-19 or post COVID-19 condition (PCC). It included 40 studies with 2445 participants; patients were adults hospitalized in any setting or discharged at home, with any COVID-19 severity or PCC. Interventions included pulmonary rehabilitation, self-activities, qigong exercise and acupressure rehabilitation program (QARP), yoga and naturopathy, Mandala coloring, cognitive motor training, and FES-cycling. Comparisons were usual care or no intervention. Pooled analyses compared pulmonary rehabilitation with usual care in post COVID-19 patients: exercise capacity favored pulmonary rehabilitation (MD 65.06, 95% CI 42.87 to 87.25; 2 studies, 184 participants); FEV1 favored pulmonary rehabilitation (MD 0.16, 95% CI 0.05 to 0.28; 2 studies, 179 participants); FEV1/FVC favored pulmonary rehabilitation (MD 0.05, 95% CI 0.01 to 0.09; 2 studies, 174 participants); FVC showed no effect (MD 0.19, 95% CI -0.03 to 0.42; 2 studies, 179 participants). Self-activities plus usual care compared with usual care showed an anxiety effect (MD -12.03, 95% CI -21.16 to -2.90; 2 studies, 207 participants). Narrative findings said QARP and “twist and raise” walking technique seem to reduce dyspnea and weakness; yoga and naturopathy, Mandala coloring, and respiratory exercise seem to reduce anxiety and depression; cognitive motor training seems to improve cognitive function; FES-cycling seems useful for erect position restoration and walking capacity. Li 2022 reported no serious adverse events; another study reported headache and dizziness events but no significant difference between groups. Worsening or stopping was not reported. The authors state very uncertain evidence and very low certainty.

  6. Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
    Summary

    This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.

  7. Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.2025 · review
    Summary

    This scoping review asked which interventions may support return-to-work (RTW) or work ability in people living with Long COVID. The authors searched five electronic databases and grey literature up to January 3, 2025, and included 19 intervention studies and 12 clinical practice guidelines; study designs included cohort, quasi-experimental, observational, interventional, RCT and case-report designs. No comparison group was analysed. Interventions included multimodal and interdisciplinary work-focused rehabilitation, psychoeducation, pacing, breathing strategies, cognitive rehabilitation and workplace RTW planning, plus enhanced external counterpulsation, CICT and pulsed electromagnetic field therapy. Reported durations included a 3-day concentrated program, a 36-hour CICT intervention, and follow-up at six months and one-year. Findings varied: some studies reported improvement in workability, sick leave, fatigue, functional status, cognitive function or RTW; others reported no RTW improvement (Derksen et al. 2023), no significant overall RTW enhancement with physical conditioning (Hasenoehrl et al. 2023), 72% still unable to RTW after rehabilitation (Muller et al. 2023), and a 2% RTW improvement with a psychotherapy-based inpatient program (Kupferschmitt et al. 2023). The review states that graded exercise is contraindicated for people with PEM and that interventions ignoring PEM risk worsening fatigue.

  8. Beyond the basics: exploring non-conventional treatment for fatigue in post-acute COVID-19 syndrome.2025 · review
    Summary

    This narrative review examined non-conventional treatments for fatigue in post-acute COVID-19 syndrome (PACS). The review itself reports no enrolled or analysed participants, setting, or follow-up. It summarizes a 388-participant study of QJYQ 10 grams twice daily for 14 days versus standard rehabilitation, with significant Borg scale improvement in the intervention group; a 30-survivor vitamin-minerals study; a 201-subject vitamin-minerals study with chronic fatigue score enhancements in 77% and 90% at 14 days and 28 days; a 66-survivor case-control study (33 intervention, 33 control) of a 10-amino-acid supplement for 8-week; a 44-female aromatherapy study for 14 days with no reported adverse effects; a 27-patient SingStrong program; a 50-year-old acupuncture case; a 55-year-old man HBOT case; and a 55-year-old female PEMF case with brief fatigue inventory score from 6.33 at baseline to 0.11 at 6 weeks post-treatment. Outcomes included fatigue scales, muscle strength, physical performance, quality of life, cognitive function, and physical capacity. No worsening or stopping is reported. No limitations are stated.

  9. CLINICAL ASPECTS OF NEUROLOGICAL MANIFESTATIONS OF LONG COVID AND PROSPECTS FOR PHYSIOTHERAPEUTIC INTERVENTIONS (REVIEW OF LITERATURE)2025 · review
    Summary

    This literature review examined neurological and neuropsychiatric manifestations of Long COVID and possible physiotherapeutic interventions. It did not report its own patient cohort; it summarized published reports on pulsed electromagnetic field (PEMF) therapy and repetitive transcranial magnetic stimulation (rTMS), including tDCS and TMS. For PEMF, a cited pilot randomized trial reported improvements in functional capacity and quality of life versus placebo; no serious adverse events were noted. A cited clinical observation described immediate improvement in neuromuscular interaction and sustained benefit over six months. For rTMS, a Japanese case series (n>20) suggested reduced depressive symptoms and enhanced cognitive function. A 2023 series documented reductions in chronic fatigue and cognitive slowing. A 2024 pilot (n=4) reported good tolerability and short-term cognitive gains, and single-case reports associated 10 iTBS sessions with mood/cognitive improvements. A cited systematic review of 19 studies found tDCS and TMS as potential modalities but highly inconsistent findings. Harms included transient local sensations during PEMF sessions and transient scalp tingling or headache with TMS; serious adverse events were not reported. The authors stated the evidence base is underpowered pilot data and case series, utility is unproven, and larger randomized trials with standardized protocols are needed.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime